Busulfan etkileşimleri

Busulfan (Myleran, Busulfex) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 37 belgelenmiş etkileşim var: 3 majör, 4 orta, 30 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 0 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.

Etikete göre etkileşimler

Majör etkileşimler (3)

  • Do not administer bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride concomitantly with busulfan unless the benefit outweighs the risk. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

  • MetronidazolantibiyotikMajör

    Busulfan : Increased busulfan serum concentrations; avoid concomitant use, monitor for plasma concentrations and adjust the busulfan dose accordingly. (Metronidazol etiketi, İlaç etkileşimleri)

  • SiklofosfamidimmünosüpresanMajör

    Hepatic veno-occlusive disease, which may be life threatening, has been reported in patients receiving busulfan, usually in combination with cyclophosphamide or other chemotherapeutic agents prior to bone marrow transplantation. (Busulfan etiketi, Uyarılar)

Orta düzey etkileşimler (4)

  • Deferasiroksdemir takviyesiOrta

    Deferasirox increases exposure of busulfan. (Deferasiroks etiketi, İlaç etkileşimleri)

  • Hemorrhagic cystitis is dose‑dependent and the risk is increased with past or concomitant radiation of the bladder or busulfan treatment. (İfosfamid etiketi, Uyarılar ve önlemler)

  • İtrakonazolazol antifungalOrta

    The concomitant systemic administration of itraconazole to patients receiving high-dose MYLERAN may result in reduced busulfan clearance (see CLINICAL PHARMACOLOGY). (Busulfan etiketi, İlaç etkileşimleri)

  • Hepatic Veno-Occlusive Disease Hepatic veno-occlusive disease may occur in patients who have received high-dose TEPADINA in conjunction with busulfan and cyclophosphamide [ see Adverse Reactions (6.1) ]. (Tiotepa etiketi, Uyarılar ve önlemler)

Minör değinmeler (30)

  • Azelastin ve flutikazonantihistaminikMinör

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan etiketi, Uyarılar)

  • BeklometazonkortikosteroidMinör

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan etiketi, Uyarılar)

  • BetametazonkortikosteroidMinör

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan etiketi, Uyarılar)

  • BudesonidkortikosteroidMinör

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan etiketi, Uyarılar)

  • Budesonid ve formoterolkortikosteroidMinör

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan etiketi, Uyarılar)

  • DeflazakortkortikosteroidMinör

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan etiketi, Uyarılar)

  • DeksametazonkortikosteroidMinör

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan etiketi, Uyarılar)

  • DesonidkortikosteroidMinör

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan etiketi, Uyarılar)

  • FludrokortizonkortikosteroidMinör

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan etiketi, Uyarılar)

  • FlunisolidkortikosteroidMinör

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan etiketi, Uyarılar)

  • FluosinonidkortikosteroidMinör

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan etiketi, Uyarılar)

  • FlutikazonkortikosteroidMinör

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan etiketi, Uyarılar)

  • Flutikazon ve salmeterolkortikosteroidMinör

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan etiketi, Uyarılar)

  • HalobetazolkortikosteroidMinör

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan etiketi, Uyarılar)

  • HidrokortizonkortikosteroidMinör

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan etiketi, Uyarılar)

  • KlobetazolkortikosteroidMinör

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan etiketi, Uyarılar)

  • Levotiroksintiroid hormonuMinör

    Cytologic abnormalities characterized by giant, hyperchromatic nuclei have been reported in lymph nodes, pancreas, thyroid, adrenal glands, liver, and bone marrow. (Busulfan etiketi, Uyarılar)

  • Levotiroksin ve liyotironintiroid hormonuMinör

    Cytologic abnormalities characterized by giant, hyperchromatic nuclei have been reported in lymph nodes, pancreas, thyroid, adrenal glands, liver, and bone marrow. (Busulfan etiketi, Uyarılar)

  • Liyotironintiroid hormonuMinör

    Cytologic abnormalities characterized by giant, hyperchromatic nuclei have been reported in lymph nodes, pancreas, thyroid, adrenal glands, liver, and bone marrow. (Busulfan etiketi, Uyarılar)

  • MerkaptopürinantimetabolitMinör

    During the pregnancy that resulted in the malformed infant, the mother received x-ray therapy early in the first trimester, mercaptopurine until the third month, then busulfan until delivery. (Busulfan etiketi, Uyarılar)

  • MetilprednizolonkortikosteroidMinör

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan etiketi, Uyarılar)

  • Metimazolantitiroid ilaçMinör

    Cytologic abnormalities characterized by giant, hyperchromatic nuclei have been reported in lymph nodes, pancreas, thyroid, adrenal glands, liver, and bone marrow. (Busulfan etiketi, Uyarılar)

  • MometazonkortikosteroidMinör

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan etiketi, Uyarılar)

  • Olopatadin ve mometazonantihistaminikMinör

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan etiketi, Uyarılar)

  • PrednizolonkortikosteroidMinör

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan etiketi, Uyarılar)

  • PrednizonkortikosteroidMinör

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan etiketi, Uyarılar)

  • Propiltiourasilantitiroid ilaçMinör

    Cytologic abnormalities characterized by giant, hyperchromatic nuclei have been reported in lymph nodes, pancreas, thyroid, adrenal glands, liver, and bone marrow. (Busulfan etiketi, Uyarılar)

  • SiklesonidkortikosteroidMinör

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan etiketi, Uyarılar)

  • Teriparatidtiroid hormonuMinör

    Cytologic abnormalities characterized by giant, hyperchromatic nuclei have been reported in lymph nodes, pancreas, thyroid, adrenal glands, liver, and bone marrow. (Busulfan etiketi, Uyarılar)

  • TriamsinolonkortikosteroidMinör

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan etiketi, Uyarılar)

Kullandığınız her şeyi Busulfan ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.

Sorgulama aracında aç

Tıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.